Is oncolytic therapy safe for patients receiving pembrolizumab?

Zenodo (CERN European Organization for Nuclear Research) 2026 Open access

Read full text
Authors: Tripdatabase
DOI: 10.5281/zenodo.18271690
Cited by: 0

Abstract

Oncolytic therapy combined with pembrolizumab appears to have a manageable safety profile, with studies indicating few serious treatment-related adverse events.

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Virus-based gene therapy research Immunotherapy and Immune Responses

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
16 January 2026